Angiogenèse et radiothérapie : tout ce qu'un oncologue radiothérapeute doit savoir

R. Mazeron; J. Bourhis; E. Deutsch

doi:10.1016/j.canrad.2007.12.002

Angiogenèse et radiothérapie : tout ce qu'un oncologue radiothérapeute doit savoir

R. Mazeron, J. Bourhis, E. Deutsch

Résultats de recherche: Contribution à un journal › Brève enquête › Revue par des pairs

8 Citations (Scopus)

Résumé

Angiogenesis is a crucial requirement for tumorogenesis, providing oxygen and nutrient supply necessary for tumor growth and metastasis. This is a complex phenomenon regulated by many factors that can now be targeted by novel anti-cancer therapies. Antiangiogenic approaches have shown positive results in clinical trials and are now approved as standard of care in medical oncology. Many clinical trials are evaluating antiangiogenic agents in association with radiotherapy. This review aims to summarize the knowledge useful to the understanding of these novel therapies and their potential in combination with radiotherapy.

Titre traduit de la contribution	Angiogenesis: All a radiation oncologist should know
langue originale	Français
Pages (de - à)	50-60
Nombre de pages	11
journal	Cancer/Radiotherapie
Volume	12
Numéro de publication	1
Les DOIs	https://doi.org/10.1016/j.canrad.2007.12.002
état	Publié - 1 janv. 2008

mots-clés

Antiangiogenesis
Radiotherapy
VEGF

Accès au document

10.1016/j.canrad.2007.12.002

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{d5a4c982a1ed4cedb09683df1cd2a112,

title = "Angiogen{\`e}se et radioth{\'e}rapie : tout ce qu'un oncologue radioth{\'e}rapeute doit savoir",

abstract = "Angiogenesis is a crucial requirement for tumorogenesis, providing oxygen and nutrient supply necessary for tumor growth and metastasis. This is a complex phenomenon regulated by many factors that can now be targeted by novel anti-cancer therapies. Antiangiogenic approaches have shown positive results in clinical trials and are now approved as standard of care in medical oncology. Many clinical trials are evaluating antiangiogenic agents in association with radiotherapy. This review aims to summarize the knowledge useful to the understanding of these novel therapies and their potential in combination with radiotherapy.",

keywords = "Antiangiogenesis, Radiotherapy, VEGF",

author = "R. Mazeron and J. Bourhis and E. Deutsch",

year = "2008",

month = jan,

day = "1",

doi = "10.1016/j.canrad.2007.12.002",

language = "Fran{\c c}ais",

volume = "12",

pages = "50--60",

journal = "Cancer/Radiotherapie",

issn = "1278-3218",

number = "1",

}

TY - JOUR

T1 - Angiogenèse et radiothérapie

T2 - tout ce qu'un oncologue radiothérapeute doit savoir

AU - Mazeron, R.

AU - Bourhis, J.

AU - Deutsch, E.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Angiogenesis is a crucial requirement for tumorogenesis, providing oxygen and nutrient supply necessary for tumor growth and metastasis. This is a complex phenomenon regulated by many factors that can now be targeted by novel anti-cancer therapies. Antiangiogenic approaches have shown positive results in clinical trials and are now approved as standard of care in medical oncology. Many clinical trials are evaluating antiangiogenic agents in association with radiotherapy. This review aims to summarize the knowledge useful to the understanding of these novel therapies and their potential in combination with radiotherapy.

AB - Angiogenesis is a crucial requirement for tumorogenesis, providing oxygen and nutrient supply necessary for tumor growth and metastasis. This is a complex phenomenon regulated by many factors that can now be targeted by novel anti-cancer therapies. Antiangiogenic approaches have shown positive results in clinical trials and are now approved as standard of care in medical oncology. Many clinical trials are evaluating antiangiogenic agents in association with radiotherapy. This review aims to summarize the knowledge useful to the understanding of these novel therapies and their potential in combination with radiotherapy.

KW - Antiangiogenesis

KW - Radiotherapy

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=39949084675&partnerID=8YFLogxK

U2 - 10.1016/j.canrad.2007.12.002

DO - 10.1016/j.canrad.2007.12.002

M3 - Brève enquête

C2 - 18243753

AN - SCOPUS:39949084675

SN - 1278-3218

VL - 12

SP - 50

EP - 60

JO - Cancer/Radiotherapie

JF - Cancer/Radiotherapie

IS - 1

ER -